P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
A 2D perchlorinated sp2-carbon framework
Cheng-Hao Liu,Yoko Sakai-Otsuka,Paul G. Richardson,Muhammad Rizwan Niazi,Ehsan Hamzehpoor,Thaksen Jadhav,Akaela Michels-Gualteri,Muralee Murugesu,Dmytro F. Perepichka +8 more
TL;DR: In this paper , an organic framework with perchlorotriphenylmethyl (PTM) radical nodes, synthesized through dehalogenative thermolysis polymerization of tris(iodotetrachlorophenyl)methane, is reported.
Journal ArticleDOI
Effect of a novel agent, SL-401, targeting interleukin-3 receptor (IL-3R) on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and osteolytic bone disease.
Dharminder Chauhan,Arghya Ray,Deepika Sharma Das,Vincent Macri,Christopher Brooks,Paul G. Richardson,Eric K. Rowinsky,Kenneth C. Anderson +7 more
TL;DR: The effect of SL-401, a novel targeted therapy directed to IL-3R, on pDC-induced MM cell growth and osteoclast (OCL) formation is examined.
Journal ArticleDOI
Adults Receiving Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Stem Cell Transplantation (HSCT): Final Results from the Expanded-Access Program
Paul G. Richardson,Joseph H. Antin,Sergio Giralt,Robert J. Ryan,Wei Liang,Robin Hume,William Tappe,Nancy A. Kernan +7 more
TL;DR: The T-IND trial as mentioned in this paper was the largest prospective evaluation of defibrotide and found that the most common adverse events in adults with VOD/SOS onset after day +21 (ie, late-onset, per EBMT proposed criteria for adults).
Journal ArticleDOI
Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study,
Sundar Jagannath,Sagar Lonial,Andrzej Jakubowiak,Thierry Facon,Ravi Vij,Marc S. Raab,Darrell White,Min-Hui Wang,Teresa Parli,Blake J Bartlett,Anil K. Singhal,Paul G. Richardson +11 more
TL;DR: A subset analysis of patients with relapsed multiple myeloma who have high risk cytogenetic features, Stage 23 disease, or are refractory respond suboptimally to current therapies according to the International Myeloma Working Group (IMWG) criteria, finding the elotuzumab- dexamethasone combination was generally well tolerated.
Journal ArticleDOI
Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN
Rebecca Silbermann,Jacob P. Laubach,Jonathan L. Kaufman,Douglas W. Sborov,Brandi Reeves,Cesar Rodriguez,Ajai Chari,Luciano J. Costa,Larry D. Anderson,Nitya Nathwani,Nina Shah,Naresh Bumma,Sarah A. Holstein,Caitlin Costello,Andrzej Jakubowiak,Robert Z. Orlowski,K. Shin,Andrew J. Cowan,Katharine S. Gries,Huiling Pei,Annelore Cortoos,Sharmila Patel,Thomas S. Lin,Paul G. Richardson,Saad Usmani,Peter M. Voorhees +25 more
TL;DR: In this paper , a multicenter, randomized, open-label, active-controlled, phase 2 study comparing daratumumab in combination with bortezomib, lenalidomide and dexamethasone (D-RVd) vs RVd in transplant eligible patients (pts) with newly diagnosed multiple myeloma (NDMM).